SLC2A1 and cancer: After entering the cells, FOXM1-PROTAC induces the degradation of FOXM1 protein, inhibits the viability, migration and invasion of various cancer cell lines. At the same time, it down-regulates the protein expression levels of the glucose transporter GLUT1 and the immune checkpoint PD-L1, and reduces the glucose metabolism of cancer cells.